Tasimelteon for the treatment of non-24-hour sleep-wake disorder
- PMID: 25685859
- DOI: 10.1358/dot.2015.51.1.2258364
Tasimelteon for the treatment of non-24-hour sleep-wake disorder
Abstract
Tasimelteon (Hetlioz®), a melatonin receptor agonist, is the first, and, at the time of the publication, the only drug to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24-hour sleep-wake disorder (non-24). This circadian rhythm disorder occurs most commonly in blind individuals without light perception, and it results from their inability to entrain to the 24-hour photoperiod, although the indication does not specify a particular patient population. Non-24 is characterized by a persistent cycle of nighttime insomnia and daytime sleepiness, alternating with asymptomatic periods depending on an individual's degree of circadian rhythm synchronization with the photoperiod at any particular time. Phase II clinical trials in healthy individuals confirmed the circadian phase-shifting potential of tasimelteon. Phase III trials in totally blind subjects diagnosed with non-24 demonstrated the efficacy of tasimelteon in reducing both nighttime wakefulness and daytime napping. Physiologic monitoring revealed that tasimelteon resulted in a higher proportion of individuals becoming entrained to the 24-hour cycle compared with placebo. Safety assessments indicated that tasimelteon is well tolerated, with the most common adverse events being headache, alanine aminotransferase elevation, nightmares or unusual dreams, and upper respiratory or urinary tract infections. Tasimelteon is available as a capsule in a single 20-mg dose and it must be obtained through Vanda Pharmaceutical's HetliozSolutions program with dispensing through a specialty pharmacy. Safety studies in blind individuals diagnosed with non-24 are ongoing and a future clinical trial with Smith-Magenis syndrome patients is planned.
Keywords: Circadian rhythm; Melatonin; Non-24-hour sleep-wake disorder; Tasimelteon.
Copyright 2015 Prous Science, S.A.U. or its licensors. All rights reserved.
Similar articles
-
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.Lancet. 2015 Oct 31;386(10005):1754-64. doi: 10.1016/S0140-6736(15)60031-9. Epub 2015 Aug 4. Lancet. 2015. PMID: 26466871 Clinical Trial.
-
Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.CNS Spectr. 2014 Dec;19(6):475-8. doi: 10.1017/S1092852914000637. CNS Spectr. 2014. PMID: 25422900 Review.
-
Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.J Pharm Pract. 2015 Oct;28(5):473-8. doi: 10.1177/0897190014544792. Epub 2014 Aug 3. J Pharm Pract. 2015. PMID: 25092604 Review.
-
Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder.Med Lett Drugs Ther. 2014 Apr 28;56(1441):34-5. Med Lett Drugs Ther. 2014. PMID: 24759294 No abstract available.
-
Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.Curr Opin Investig Drugs. 2009 Jul;10(7):691-701. Curr Opin Investig Drugs. 2009. PMID: 19579175
Cited by
-
Cardioprotective Melatonin: Translating from Proof-of-Concept Studies to Therapeutic Use.Int J Mol Sci. 2019 Sep 5;20(18):4342. doi: 10.3390/ijms20184342. Int J Mol Sci. 2019. PMID: 31491852 Free PMC article. Review.
-
Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep.Front Endocrinol (Lausanne). 2019 Mar 1;10:87. doi: 10.3389/fendo.2019.00087. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 30881340 Free PMC article. Review.
-
Sleep Medicine: Insomnia and Sleep.Mo Med. 2019 Jan-Feb;116(1):68-75. Mo Med. 2019. PMID: 30862990 Free PMC article. Review.
-
Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies.Nat Sci Sleep. 2016 Jan 14;8:21-33. doi: 10.2147/NSS.S76706. eCollection 2016. Nat Sci Sleep. 2016. PMID: 26834500 Free PMC article. Review.
-
Synchrony and desynchrony in circadian clocks: impacts on learning and memory.Learn Mem. 2015 Aug 18;22(9):426-37. doi: 10.1101/lm.038877.115. Print 2015 Sep. Learn Mem. 2015. PMID: 26286653 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources